Complain about a product or service

Merck Hopes New Study Will Help In Vioxx Defense

By Mark Huffman
ConsumerAffairs.com

May 12, 2006

Related Stories • Pfizer Pays Record $2.3 Billion Settlement Over Illegal Marketing Charges • Court Snuffs Vioxx Suit • Pfizer Pays $894 Million to Settle NSAID Claims • Researchers Claim Vioxx Safety Study Was Actually Marketing Plan • First Vioxx Judgment Overturned On Appeal • Merck Agrees to Pay $58 Million to Settle Vioxx Claims • Researchers Claim Merck Cooked Vioxx Data • Common Pain Relievers May Boost Muscle Mass • More Painkillers Can Cause More Pain • Merck Caves, Agrees To $4.85 Billion Vioxx Settlement • New York Sues Vioxx Maker over Drug’s Risks • Merck Wins Vioxx Case In Illinois • Judge Rules Out Vioxx "Super" Class Action • FDA Critic Blasts Merck's Vioxx Replacement • Merck Loses New Orleans Vioxx Case • Merck Wins Latest Vioxx Suit • Vioxx Study Authors Backtrack On Claim • Older Painkillers May Increase Heart Attack Risk • More about Vioxx --- Other NSAIDs • Bextra • Celebrex • Dangers of Other Vioxx-Type Drugs • Vioxx Alternatives • Aleve Ingredient Seen as Health Risk

Merck & Co., the defendant in numerous lawsuits over its withdrawn painkiller Vioxx, is pointing to a new study that shows patients who stopped taking the drug are in little danger.

The drug was withdrawn after patients in clinical trials suffered a higher proportion of heart attacks and strokes than those taking a placebo.

Attorneys for the besieged pharmaceutical giant say a follow-up examination of participants in a three-year study shows that patients who stopped taking Vioxx for one year had no greater risk of heart attacks and strokes than patients who took placebos during the same study.

Why is that important?

Kenneth Frazier, Merck's chief lawyer, says the company faces thousands of lawsuits from people who blame the company for strokes or heart attacks suffered after they discontined use of the drug.

"We believe the data does not provide a valid basis for claims after patients stopped taking the medicine," he said.

Some Wall Street analysts have predicted the Vioxx cases will drag on for a decade or longer and eventually cost the company billions of dollars in legal fees and damages. So far, Merck has resisted a group settlement and has vowed to contest each case individually.

To date, the company has faced six Vioxx damages suits, winning three and losing three.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share		Follow us on Twitter.